These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 32777794)

  • 1. Atrial fibrillation in acute coronary syndrome: patient characteristics and appropriate utilisation of anti-thrombotic therapy in New Zealand (ANZACS-QI 39).
    Ho CY; Nunn C; White J; Kerr A; Lee M
    N Z Med J; 2020 Jul; 133(1519):41-54. PubMed ID: 32777794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antithrombotic therapies in Canadian atrial fibrillation patients with concomitant coronary artery disease: Insights from the CONNECT AF + PCI-II program.
    Chow JK; Bagai A; Tan MK; Har BJ; Yip AMC; Paniagua M; Elbarouni B; Bainey KR; Paradis JM; Maranda R; Cantor WJ; Eisenberg MJ; Dery JP; Madan M; Cieza T; Matteau A; Roth S; Lavi S; Glanz A; Gao D; Tahiliani R; Welsh RC; Kim HH; Robinson SD; Daneault B; Chong AY; Le May MR; Ahooja V; Gregoire JC; Nadeau PL; Laksman Z; Heilbron B; Yung D; Minhas K; Bourgeois R; Overgaard CB; Bonakdar H; Logsetty G; Lavoie AJ; De LaRochelliere R; Mansour S; Spindler C; Yan AT; Goodman SG;
    J Cardiol; 2023 Aug; 82(2):153-161. PubMed ID: 36931433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of double vs. triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: a collaborative meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials.
    Gargiulo G; Cannon CP; Gibson CM; Goette A; Lopes RD; Oldgren J; Korjian S; Windecker S; Esposito G; Vranckx P; Valgimigli M
    Eur Heart J Cardiovasc Pharmacother; 2021 Apr; 7(FI1):f50-f60. PubMed ID: 33119069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-discharge antithrombotic management and clinical outcomes of patients with new-onset or pre-existing atrial fibrillation and acute coronary syndromes undergoing coronary stenting: Follow-up data of the MATADOR-PCI study.
    De Luca L; Di Lenarda A; Rubboli A; Bolognese L; Gonzini L; Fortuni F; Navazio A; Poletti F; Ledda A; Urbinati S; Gabrielli D; Gulizia MM;
    Eur J Intern Med; 2021 Jun; 88():28-34. PubMed ID: 33838988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antithrombotic management of patients with acute coronary syndrome and atrial fibrillation undergoing coronary stenting: a prospective, observational, nationwide study.
    De Luca L; Rubboli A; Bolognese L; Gonzini L; Urbinati S; Murrone A; Scotto di Uccio F; Ferrari F; Lucà F; Caldarola P; Lucci D; Gabrielli D; Di Lenarda A; Gulizia MM;
    BMJ Open; 2020 Dec; 10(12):e041044. PubMed ID: 33371033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antithrombotic therapy in coronary artery disease patients with atrial fibrillation.
    Wei L; Su E; Liu W; Xing W; Liu X; Zhang Y; Wang S; Cheng Q; Qi D; Gao C
    BMC Cardiovasc Disord; 2020 Jul; 20(1):323. PubMed ID: 32631244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological therapy following acute coronary syndromes in patients with atrial fibrillation: how do we balance ischaemic risk with bleeding risk?
    Fake AL; Harding SA; Matsis PP; Larsen PD
    N Z Med J; 2016 May; 129(1435):39-49. PubMed ID: 27355167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apixaban versus PhenpRocoumon: Oral AntiCoagulation plus antiplatelet tHerapy in patients with Acute Coronary Syndrome and Atrial Fibrillation (APPROACH-ACS-AF): Rationale and design of the prospective randomized parallel-group, open-label, blinded-endpoint, superiority, multicenter-trial of a triple therapy versus a dual therapy in patients with Atrial Fibrillation and Acute Coronary Syndrome undergoing coronary stenting.
    Riesinger L; Strobl C; Leistner DM; Gori T; Akin I; Mehr M; Kellnar A; Mahabadi AA; Bogossian H; Block M; Edelmann F; Sarafoff N; Sibbing D; Ince H; Rassaf T; Mansmann U; Mehilli J; Kääb S; Hausleiter J; Massberg S; Wakili R
    Int J Cardiol Heart Vasc; 2021 Aug; 35():100810. PubMed ID: 34258380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Anticoagulation status and adherence in patients with atrial fibrillation hospitalized for ACS and the impact on 1-year prognosis: a multicenter cohort study].
    Zhu LY; Li Q; Yu LY; Liu Y; Chen YN; Wang Z; Zhang SY; Li J; Liu Y; Zhao YL; Xi Y; Pi L; Sun YH
    Zhonghua Xin Xue Guan Bing Za Zhi; 2023 Jul; 51(7):731-741. PubMed ID: 37460427
    [No Abstract]   [Full Text] [Related]  

  • 10. Intracranial haemorrhages vs. stent thromboses with direct oral anticoagulant plus single antiplatelet agent or triple antithrombotic therapy: a meta-analysis of randomized trials in atrial fibrillation and percutaneous coronary intervention/acute coronary syndrome patients.
    Galli M; Andreotti F; Porto I; Crea F
    Europace; 2020 Apr; 22(4):538-546. PubMed ID: 31942971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world antithrombotic therapies and clinical outcomes after second-generation drug-eluting stent implantation in patients with atrial fibrillation: a multi-center cohort study.
    Otsuki H; Yamaguchi J; Kamishima K; Arashi H; Hagiwara N
    Heart Vessels; 2018 Sep; 33(9):986-996. PubMed ID: 29549436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome and / or undergoing percutaneous coronary intervention.
    Mihajlovic M; Marinkovic M; Kozieł M; Mujovic N; Lip GYH; Potpara TS
    Kardiol Pol; 2020 Jun; 78(6):512-519. PubMed ID: 32543800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antithrombotic strategies and outcomes in acute coronary syndrome with atrial fibrillation.
    Chamberlain AM; Gersh BJ; Mills RM; Klaskala W; Alonso A; Weston SA; Roger VL
    Am J Cardiol; 2015 Apr; 115(8):1042-8. PubMed ID: 25726381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of known or new-onset atrial fibrillation on 2-year cardiovascular event rate in patients with acute coronary syndromes: results from the prospective EPICOR Registry.
    Zeymer U; Annemans L; Danchin N; Pocock S; Newsome S; Van de Werf F; Medina J; Bueno H
    Eur Heart J Acute Cardiovasc Care; 2019 Mar; 8(2):121-129. PubMed ID: 29611427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Balancing the Risk of Bleeding and Stroke in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the AVIATOR Registry).
    Mennuni MG; Halperin JL; Bansilal S; Schoos MM; Theodoropoulos KN; Meelu OA; Sartori S; Giacoppo D; Bernelli C; Moreno PR; Krishnan P; Baber U; Lucarelli C; Dangas GD; Sharma SK; Kini AS; Tamburino C; Chieffo A; Colombo A; Presbitero P; Mehran R
    Am J Cardiol; 2015 Jul; 116(1):37-42. PubMed ID: 25956624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease.
    Lopes RD; Rao M; Simon DN; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Go AS; Hylek EM; Kowey P; Piccini JP; Singer DE; Chang P; Peterson ED; Mahaffey KW
    Am J Med; 2016 Jun; 129(6):592-599.e1. PubMed ID: 26797080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double Antithrombotic versus Triple Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndrome.
    Dharma S
    Int J Angiol; 2020 Jun; 29(2):81-87. PubMed ID: 32476809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bleeding and ischaemic outcomes in patients treated with dual or triple antithrombotic therapy: systematic review and meta-analysis.
    Haller PM; Sulzgruber P; Kaufmann C; Geelhoed B; Tamargo J; Wassmann S; Schnabel RB; Westermann D; Huber K; Niessner A; Gremmel T
    Eur Heart J Cardiovasc Pharmacother; 2019 Oct; 5(4):226-236. PubMed ID: 31198930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: JACC State-of-the-Art Review.
    Capodanno D; Huber K; Mehran R; Lip GYH; Faxon DP; Granger CB; Vranckx P; Lopes RD; Montalescot G; Cannon CP; Ten Berg J; Gersh BJ; Bhatt DL; Angiolillo DJ
    J Am Coll Cardiol; 2019 Jul; 74(1):83-99. PubMed ID: 31272556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials.
    Gargiulo G; Goette A; Tijssen J; Eckardt L; Lewalter T; Vranckx P; Valgimigli M
    Eur Heart J; 2019 Dec; 40(46):3757-3767. PubMed ID: 31651946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.